drugset / Trial / NCT06656702
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
Phase 0
Recruiting
24 enrolled
Johns Hopkins University
Congressionally Directed Medical Research Programs · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population.
Timeline
- Start
- 2025-04-09
- Primary completion
- 2027-01-30
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 15 mg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |